Fifty patients with acute promyelocytic leukemia (APL) have been treated with all-trans retinoic acid (RA). In vitro induced differentiation of primarily cultured bone marrow cells from the patients, colony-forming unit granulocyte-macrophage (CFU-GM) and L-CFU colony-forming assays, and karyotype analysis were performed over the treatment course. The very high bone marrow complete remission (CR) rate (94%) suggested that all-trans RA was superior to conventional chemotherapeutic regimens for the treatment of APL. The leukemic clone was reduced by RA-induced terminal differentiation and loss of proliferation capacity of leukemic cells. Relapse after CR in about 40% of patients was the major reason for the failure of the RA treatment. Patients who relapsed after a chemotherapy-maintained CR could be effectively reinduced to second CR by RA. However, if relapse occurred after a CR maintained by both RA and chemotherapy, the sensitivity of newly emerged leukemic clones to RA was greatly reduced. Therefore, it is suggested that RA should be replaced by conventional chemotherapy as soon as CR is achieved. Laboratory studies proved valuable in selecting cases for RA therapy and in predicting therapeutic effects and prognosis.

Three eggplant cultivars were inoculated with Verticillium dahliae Kleb. to assess their resistance to Verticillium wilt. Solanum tor was resistant, "Liyuanziqie" was tolerant, and "Xi'anlvqie" susceptible. The disease incidence and disease index of Verticillium wilt and the amount of V. dahliae in rhizospheric soil, variation of microbial composition, the allelopathy of root exudates to mycelium growth of V. dahliae and the chemical substances of root exudates from eggplant cultivars with different resistance to Verticillium wilt were investigated in this experiment. The results showed that the root exudates of resistant type could not only affect the growth and development of V. dahliae, but also influence V. dahliae indirectly through regulating soil microbial community composition. This may be one of the reasons for the increase of disease resistance. However, the susceptible type exhibited an opposite trend. It was inferred that the resistant type contained some particular components, such as acohd, amide, pyranoid, fluorene, while the susceptible one comprised more types of components, that is, ketone, phenol, ester and phenolic acid.

In this single-center, retrospective study we evaluated clinicopathological features, frontline treatment and survival outcomes of 63 patients with an ascertained pathological diagnosis of SM treated in our center from 2000 until 2020.Results: The median age was 71 years (range 45-88), 57 (90%) patients were male. At the time of diagnosis, 52 (83%) patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) 1. Twenty (32%) patients received best supportive care (BSC), 39 (62%) received first-line chemotherapy (CT), 3 (5%) trimodality treatment and 1 (2%) patient underwent surgery only. In the subgroup of patients with first-line CT, 26 (67%) were treated with a platinum-based doublet-CT, while 13 (33%) received single agent CT (mono-CT). Patients treated with CT had a median progression-free survival (PFS) of 2 months (95% confidence interval (CI) 1.24-2.76) and a median OS of 7 months (95% CI 5.26-8.74). Compared with patients with mono-CT, patients receiving doublet-CT had a longer median OS (3 months vs. 8 months, HR 0.42 [95% CI, 0.21-0.85], p¼0.009). The median PFS was 3 months for patients receiving doublet-CT and 1 month for patients treated with mono-CT (HR 0.87 [95% CI 0.43-1.74], p¼0.63) The median OS of patients receiving BSC was 2 months (95% CI 0.95-3.05). No significant difference in OS was found when comparing mono-CT with BSC (3 vs. 2 months, HR 0.55 [95% CI, 0.26-1.17], p¼0.082) and this was consistent in the subgroup of patients aged 70 years (OS 3 vs. 2 months, HR 0.73 [95% CI 0.3-1.75], p¼0.440).Conclusions: In patients with SM not eligible for frontline platinum-based doublet-CT, treatment with single agent CT should be carefully evaluated, since the survival benefit is unclear. abstracts Annals of Oncology Volume 32 -Issue S5 -2021 S1203